Alkermes reports Q3 2026 revenue of $480.1M, GAAP profit falls 80% but EPS beats expectations

Alkermes plc announced third‑quarter 2026 results on November 3. Revenue rose 21.8% year‑over‑year to $480.1 million, driven by strong sales of the newly acquired narcolepsy drug LUMRYZ. GAAP net income dropped 80.3% to $16.3 million, giving diluted EPS of $0.09, which beat the consensus forecast of a $0.08 loss per share. The company reaffirmed its full‑year 2026 revenue guidance of $1.73‑$1.84 billion and its adjusted EBITDA target of $370‑$410 million.

The revenue beat shows top‑line momentum, but the steep profit decline highlights the cost impact of the Avadel acquisition, which may pressure cash flow. By reaffirming guidance, the company signals that the earnings dip is expected to be temporary and that underlying operations remain solid.

  • 1Total revenue for Q3 2026 was $480.1 million, up 21.8% year‑over‑year.
  • 2GAAP net income fell to $16.3 million, an 80.3% decline from $82.8 million a year earlier.
  • 3Diluted EPS was $0.09, beating analyst expectations of a $0.08 loss per share.
  • 4Adjusted EBITDA was $120.1 million, essentially flat versus $121.5 million in the prior year.
  • 5Proprietary product net sales were $417.3 million, up 31% year‑over‑year.
  • 6Full‑year 2026 revenue guidance remains $1.73 billion to $1.84 billion; adjusted EBITDA guidance $370 million to $410 million.

Sources